Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gene-based Therapies for Cardiovascular Medicine-Incorporating Molecular Medicine into Contemporary Cardiology.

The Canadian journal of cardiology·2026
Same author

A Review of the Challenge of Pre-Existing Humoral Immunity in Adeno-Associated Virus Gene Therapy and Potential Solutions.

Human gene therapy·2026
Same author

The Past, Present, and Future of Cardiac Gene Therapy.

The Canadian journal of cardiology·2026
Same author

Rationale and design of MUSIC-HFpEF: a phase 1b, pilot trial evaluating the safety and pharmacodynamic effects of AAV1.SERCA2A in heart failure with preserved ejection fraction.

Heart failure reviews·2026
Same author

Development of a Flexible Parallel Wire Robot for Epicardial Interventions.

The international journal of medical robotics + computer assisted surgery : MRCAS·2026
Same author

The second act of cardiac gene therapy.

Molecular therapy : the journal of the American Society of Gene Therapy·2025

Related Experiment Video

Updated: Jun 6, 2026

Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

Cardiac gene therapy.

Antoine H Chaanine1, Jill Kalman, Roger J Hajjar

  • 1Cardiovascular Institute, Mount Sinai School of Medicine, New York, New York 10029, USA.

Seminars in Thoracic and Cardiovascular Surgery
|November 25, 2010
PubMed
Summary
This summary is machine-generated.

Gene therapy offers a promising future for treating heart failure by targeting malfunctioning cardiomyocytes. Recombinant adeno-associated virus vectors show potential as effective delivery vehicles for these advanced therapies.

More Related Videos

A Simple and Efficient Method for In Vivo Cardiac-specific Gene Manipulation by Intramyocardial Injection in Mice
06:42

A Simple and Efficient Method for In Vivo Cardiac-specific Gene Manipulation by Intramyocardial Injection in Mice

Published on: April 16, 2018

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
08:30

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft

Published on: February 14, 2022

Related Experiment Videos

Last Updated: Jun 6, 2026

Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

A Simple and Efficient Method for In Vivo Cardiac-specific Gene Manipulation by Intramyocardial Injection in Mice
06:42

A Simple and Efficient Method for In Vivo Cardiac-specific Gene Manipulation by Intramyocardial Injection in Mice

Published on: April 16, 2018

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
08:30

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft

Published on: February 14, 2022

Area of Science:

  • Cardiology
  • Molecular Medicine
  • Gene Therapy

Background:

  • Heart failure is a progressive condition with increasing incidence and prevalence, particularly in aging populations.
  • Frequent hospitalizations in heart failure patients are linked to high mortality and morbidity rates.
  • Current understanding of heart failure's molecular pathology and pathophysiology is crucial for developing novel treatments.

Purpose of the Study:

  • To explore gene therapy as a promising approach for treating heart failure.
  • To identify novel therapeutic targets for restoring or attenuating cardiomyocyte damage.
  • To investigate efficient vector and delivery systems for gene therapy in cardiac applications.

Main Methods:

  • Focus on understanding the molecular pathology and pathophysiology of heart failure.
  • Exploration of gene therapy strategies for cardiomyocyte repair.
  • Evaluation of recombinant adeno-associated virus (AAV) vectors for cardiac gene delivery.

Main Results:

  • Gene therapy presents a promising avenue for heart failure treatment.
  • Recombinant adeno-associated virus vectors demonstrate potential as therapeutic delivery vehicles.
  • Efficient transduction, long-term expression, and immune response evasion are key considerations for vector development.

Conclusions:

  • Advancements in understanding heart failure pathogenesis can lead to innovative gene therapies.
  • Recombinant adeno-associated virus vectors are a promising platform for molecular medicine in treating heart failure.
  • Developing effective vectors and delivery methods is critical for successful cardiac gene therapy.